Eloxx doses first patients in Alport syndrome trial, clears IND for ADPKD study
Eloxx reported Q3 2026 results with two rare kidney disease programs now advancing, $56.3 million in cash, and runway into 2028.
Eloxx Pharmaceuticals said it dosed the first two patients in September 2026 in its Phase 2b "EXACT" study (NCT07523581), a global, randomized, placebo-controlled, delayed-start trial of exaluren meant to enroll 24 patients whose Alport syndrome stems from nonsense mutations in the COL4A3, COL4A4 or COL4A5 genes.1 The trial's main efficacy measure during the initial 16-week placebo-controlled period looks at changes in podocyte foot process effacement, assessed through filtration slit density on kidney biopsies, in non-U.S. pediatric patients and all adults enrolled.1 An earlier open-label Phase 2a study had found structural improvements, including reduced foot process effacement and improved GBM width, in biopsies from all three participants.1 The company said it expects to report topline data from the 16-week placebo-controlled portion in mid-2027 and final 32-week data by the end of 2027.1
Eloxx also finalized the design of a second rare kidney disease study, "EXPRESS," for nonsense mutation ADPKD. The 52-week trial will randomize roughly 60 adults with confirmed nonsense mutations in PKD1 or PKD2 one-to-one to exaluren or placebo, with the primary endpoint set as the annualized rate of change in height-adjusted total kidney volume by MRI.1 On October 29, 2026, the company announced FDA clearance of the IND for exaluren in nmADPKD, allowing it to open U.S. sites.1 Eloxx expects to dose its first EXPRESS patient in the third quarter of 2027 and report 52-week topline data in the first half of 2029.1 In pre-IND feedback, the FDA indicated that a substantial and durable effect on kidney volume growth, paired with supporting kidney function and safety data, could support a Breakthrough Therapy Designation, though any designation would depend on clinical results and further review.1
The company also added T.R. Srinivas, M.D., as Chief Medical Officer and Geno Germano to its board in October 2026.
As of September 30, 2026, Eloxx held $56.3 million in cash and cash equivalents, down from $62.0 million at June 30, 2026, which it said should fund operations into 2028.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.